CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

CRISPR Therapeutics AGNASDAQ: CRSP

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$130.05M, compared with -$101.39M a year earlier. Trailing-twelve-month EBITDA was -$482.67M.

Context

  • EBITDA amounted to 15911.3% of revenue in FY2025, up 14930.1 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 15 analysts of -$423.54M (+24.2%) for the fiscal year ending Dec 2026, a step up from the -62.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$130.05M-17.7% QoQ
Last fiscal yearDec 2025
-$558.49M-62.6% YoY
LTMSep 2026
-$482.67M-3.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.3%+12.3%+40.5 pp
1 year-62.6%+24.2%+86.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(558.49M) USD
Year-over-year change
-62.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 EBITDA of -$482.67M is the lowest of the 7 companies compared; the peer median is -$155.48M.
  • Its year-over-year change of -3.6% is the 5th highest of 7, against a peer median of +35.5%.
  • EBITDA amounts to 1917.5% of revenue for CRSP, versus a peer median of 203.9%.
CRSP Competitors Peer median
EBITDA for CRSP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026-$40.42M -143.9%—89.7%
BEAMBeam Therapeutics Inc.LTM Jun 2026-$63.18M +83.2%—40.5%
EDITEditas Medicine, Inc.LTM Mar 2026-$100.08M +56.8%—258.7%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026-$210.87M +45.6%—149.2%
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M -87.3%—261.2%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$384.61M +25.4%—581.9%
CRSPCRISPR Therapeutics AGLTM Sep 2026-$482.67M -3.6%—1917.5%
Peer median (excluding CRSP) -$155.48M+35.5%—203.9%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue913.08M436K370M35M3.51M
Cost of Revenue101.18M110.25M130.25M110.25M232.96M
Gross Profit811.9M(109.81M)239.75M(75.25M)(229.45M)
Gross Margin88.9%-25186.7%64.8%-215.0%-6537.0%
Research & Development340.57M461.65M387.33M320.65M265.33M
Selling, General & Admin99.69M102.46M76.16M72.98M73.54M
Operating Expenses438.38M563.35M462.29M391.32M338.87M
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
EBITDA397.48M(626.33M)(130.89M)(343.41M)(558.49M)
EBITDA Margin43.5%-143653.2%-35.4%-981.2%-15911.3%
Operating Income373.53M(673.16M)(222.54M)(466.57M)(568.32M)
Operating Margin40.9%-154394.7%-60.1%-1333.0%-16191.4%
Interest Income00000
Interest Expense00000
Other Income / Expenses6M22.66M71.82M103.9M(9.65M)
Income Before Tax379.53M(650.5M)(150.72M)(362.67M)(577.97M)
Pre-Tax Margin41.6%-149197.2%-40.7%-1036.2%-16466.2%
Income Tax Expense1.87M(325K)2.89M3.59M3.63M
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Net Margin41.4%-149122.7%-41.5%-1046.4%-16569.8%
EPS (Basic)4.97(8.36)(1.94)(4.34)(6.47)
EPS (Diluted)4.70(8.36)(1.94)(4.34)(6.47)
Weighted Avg Shares75.95M77.75M79.22M84.36M89.93M
Weighted Avg Shares (Diluted)80.39M77.75M79.22M84.36M89.93M

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.